Costa Esmeralda, Franqueira Nuno, Rosa Andreia M, Tavares Cristina, Quadrado Maria J, Lobo Conceição, Murta Joaquim N
Ophthalmology Unit, Centro Hospitalar e Universitário de Coimbra, Praceta Mota Pinto, 3000-075, Coimbra, Portugal,
Int Ophthalmol. 2014 Jun;34(3):477-84. doi: 10.1007/s10792-013-9833-4. Epub 2013 Jul 20.
To analyze photorefractive keratectomy (PRK) outcomes in myopia and myopic astigmatism correction using the WaveLight Allegretto Wave Eye-Q(®) excimer laser system (WaveLight Laser Technologie AG, Erlangen, Germany). 222 eyes of 151 patients underwent PRK (mean age 33.5 ± 6.8 years). Pre-operative best spectacle-corrected visual acuity (BSCVA) ranged from 0.4 to -0.1 logMAR (mean -0.03 ± 0.06). Mean spherical equivalent (SE) was -3.29 ± 1.20 D. Efficacy, predictability and safety were evaluated. Minimum follow-up was 3 months. Accountability at 3 and 6 months was 100 and 54 %, respectively (median follow-up 5 months, mean 5.2 ± 2.6 months). At 3 months, mean uncorrected visual acuity (UCVA) was -0.02 ± 0.07 logMAR, BSCVA -0.03 ± 0.05 logMAR, efficacy index 0.98 and safety index 1.02. UCVA was ≥20/16 in 40.1 %, ≥20/20 in 86.5 % and ≥20/25 in 98.2 %. Mean SE was -0.02 ± 0.20 D. Residual refractive error was ± 0.13 D in 81.5 %, ± 0.25 D in 88.7 % and ± 0.50 D in 97.7 %. At 6 months, outcomes were similar: mean UCVA was -0.02 ± 0.07 logMAR, BSCVA -0.03 ± 0.06 logMAR, efficacy index 1.00 and safety index 1.03. UCVA was ≥20/16 in 43.7 %, ≥20/20 in 86.6 % and ≥20/25 in 96.6 %. Mean SE was -0.02 ± 0.17 D. Residual refractive error was ± 0.13 D in 86.6 %, ± 0.25 D in 93.3 % and ± 0.50 D in 98.3 %. Refractive stability was achieved at 3 months. No patient lost more than one line of BSCVA. There were no retreatments. The WaveLight Allegretto Wave Eye-Q is effective, predictable and safe in low-to-moderate myopia and myopic astigmatism PRK correction.
使用鹰视酷眼(WaveLight Allegretto Wave Eye-Q®)准分子激光系统(德国爱尔朗根市的WaveLight激光技术公司)分析准分子原位角膜磨镶术(PRK)矫正近视及近视散光的效果。151例患者的222只眼接受了PRK手术(平均年龄33.5±6.8岁)。术前最佳矫正视力(BSCVA)范围为0.4至-0.1 logMAR(平均-0.03±0.06)。平均等效球镜度(SE)为-3.29±1.20 D。评估了手术的有效性、可预测性及安全性。最短随访时间为3个月。3个月及6个月时的随访率分别为100%和54%(中位随访时间5个月,平均5.2±2.6个月)。3个月时,平均裸眼视力(UCVA)为-0.02± 0.07 logMAR,BSCVA为-0.03±0.05 logMAR,有效性指数为0.98,安全性指数为1.02。UCVA≥20/16的患者占40.1%,≥20/20的患者占86.5%,≥20/25的患者占98.2%。平均SE为-0.02±0.20 D。81.5%的患者残余屈光不正±0.13 D,88.7%的患者残余屈光不正±0.25 D,97.7%的患者残余屈光不正±0.50 D。6个月时,结果相似:平均UCVA为-0.02±0.07 logMAR,BSCVA为-0.03±0.06 logMAR,有效性指数为1.00,安全性指数为1.03。UCVA≥20/16的患者占43.7%,≥20/20的患者占86.6%,≥20/25的患者占96.6%。平均SE为-0.02±0.17 D。86.6%的患者残余屈光不正±0.13 D,93.3%的患者残余屈光不正±0.25 D,98.3%的患者残余屈光不正±0.50 D。3个月时屈光状态达到稳定。没有患者的BSCVA下降超过一行。没有进行再次手术。鹰视酷眼在低至中度近视及近视散光的PRK矫正中有效、可预测且安全。